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Abstract
Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as
myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important
matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-
based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first
allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors
(UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used
to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up
(FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median
FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to
overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we
must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will
be prospectively assessed in the ALL SCTped 2012 FORUM trial.
Introduction
Most children with acute lymphoblastic leukemia (ALL)
above 2 years of age being candidate to be treated with
allogeneic hematopoietic stem cell transplantation (allo-
HSCT) receive myeloablative conditioning (MAC) with a
fractionated total body irradiation (FTBI)-containing
regimen [1–17]. It is an important matter of debate if
chemotherapy can effectively replace FTBI. Due to the
known late effects associated with the use of FTBI, which
include endocrine complications (growth impairment,
hypothyroidism, and delayed onset of puberty), infertility,
cognitive impairment, cataracts, and an increased risk for
secondary malignancies, avoidance of FTBI in the pre-
paration of allo-HSCT is desirable [18–23]. To date, it has
not been shown that FTBI can be successfully replaced by
chemotherapy during conditioning for pediatric ALL
[2, 3, 5, 24–26].
To compare outcomes of FTBI versus chemotherapy-
based conditioning (CC) in childhood ALL, we performed
this international retrospective registry-based study. The
study was initiated and conducted on behalf of the Pae-
diatric Diseases Working Party of the European Society for
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Blood and Marrow Transplantation (EBMT). The primary
endpoint was leukemia-free survival (LFS). Overall survi-
val (OS), relapse incidence (RI), nonrelapse mortality
(NRM), and incidence of acute graft versus host disease
(aGvHD) and chronic GvHD (cGvHD) were the secondary
endpoints.
Patients and methods
Children and adolescents aged between 2 and 18 years
undergoing a first allo-HSCT for ALL in first (CR1) or
second complete remission (CR2) after MAC with either
bone marrow (BM) or peripheral blood stem cells (PBSC)
from either a matched-related (MRD) or unrelated donor
(UD) between 2000 and 2012 were included in the study.
This observation period was chosen in order to obtain a
reasonable time of follow-up (FU). Moreover, the pro-
spective international randomized ALL SCTped 2012
FORUM trial was started in 2013 and is still recruiting
patients. Data were obtained from the EBMT database
ProMISe (Project Manager Internet Server) and analyzed in
the EBMT study office in Paris, France. The study was
performed in accordance with the Declaration of Helsinki.
The local institutional review board at each participating
site approved the allo-HSCT procedures. Patients and/or
their legal guardians gave written informed consent to use
clinical data and research participation. All authors had
access to the primary clinical data.
Statistical analysis
The study population was divided into two groups (patients
in CR1 and CR2). Patients’ demographic and clinical
characteristics were summarized using the median and
interquartile range for continuous variables and counts and
percentages for categorical variables. Preparative regimens
were FTBI versus CC. For both remission groups the two
conditioning regimens were compared using Fisher’s exact
test or χ² test for categorical variables and Wilcoxon rank
sum test for continuous variables [27].
Median FU was calculated using the reverse
Kaplan–Meier method. The primary endpoint was LFS
defined as the probability of being alive and free of disease
at any point in time. Thus, death or disease relapse was
treated as events. Patients alive and free of disease at their
last FU were censored [28, 29]. OS was defined as the
probability of survival irrespective of the disease state at
any point in time. Patients alive at their last FU were cen-
sored. RI was defined as the probability of having experi-
enced a relapse. Death without experiencing a relapse was
the competing event. NRM was defined as the probability of
dying without previous occurrence of a relapse, which was
considered as competing event. Incidences of aGvHD
(grade III–IV), cGvHD, and extensive cGvHD were defined
as first event of aGvHD (grade III–IV), cGvHD, and
extensive cGvHD, respectively. Death and relapse were
considered as competing events. OS, RI, NRM, and inci-
dence of acute and cGvHD were secondary endpoints [30].
The inverse probability weighting (IPW) method using
the propensity score was used to calculate weights and
adjust for confounding factors between the treatment groups
[31]. Confounding factors considered age at allo-HSCT,
year of allo-HSCT, time from diagnosis to allo-HSCT,
cytomegalovirus (CMV) serology, stem cell source, and sex
mismatch (female to male versus other).
The weighted Kaplan–Meier method was used to
estimate the standardized probability of survival for LFS
and OS, and the weighted cumulative incidence function
was used to calculate cumulative incidence of relapse
(RI), NRM, acute, and cGvHD [27–30]. P values to
evaluate survival differences between the two condition-
ing regimens were calculated using a weighted propor-
tional hazards Cox model including center as a random
effect [32]. Results were expressed as weighted prob-
abilities, weighted cumulative incidences, and hazard
ratio with their 95% confidence intervals (95% CI). All
tests were two-sided. The type 1 error rate was fixed at
0.05 for determination of factors associated with time to
event. Analyses were performed using the R statistical
software, Version 3.4.3 (R Development Core Team,
Vienna, Austria). Weights were calculated using the
twang R package [33]. The date of analysis was October
1, 2018.
Results
Characteristics of study patients
3.054 pediatric patients from European and non-European
EBMT centers in 45 countries were included. Between
2000 and 2012, 2.630 patients received a FTBI-based and
424 patients received a chemotherapy-based MAC before
allo-HSCT. 1.498 patients (49%) were transplanted in
CR1 and 1.556 (51%) in CR2. In the CR1 cohort, median
FU was 6.8 years (FTBI group) and 6.1 years (CC group),
while in the CR2 cohort, median FU was 6.2 years in the
FTBI and in the CC group. In both remission groups, the
two conditioning groups differed significantly with regard
to age at allo-HSCT, year of allo-HSCT, time from
diagnosis to allo-HSCT, stem cell source, and CMV ser-
ology (donor/patient, Table 1). These confounding factors
and the different sizes of the two conditioning groups
requested adjustment by the inverse IPW method (pro-
pensity score, see “Statistical analysis”).
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Hematopoietic stem cell donors and source
1.626 patients (53%) were grafted from an UD and 1.428
patients (47%) from a MRD. The majority (n= 2.105, 69%)
received BM and 949 patients (31%) received PBSC
(Table 1).
Preparative regimens
The most commonly applied conditioning regimens were
FTBI-based (n= 2.630). In CR1 and CR2, 1.285 (86%) and
1.345 (86%) patients, respectively, received an FTBI-based
conditioning. 424 patients received a CC (CR1: n= 213
(14%), CR2 n= 211 (14%), Table 1).
FTBI-based
FTBI/Cy (n= 990, 38%) and FTBI/Eto (n= 784, 30%)
were the two most frequent used combinations. The
remaining patients received different other FTBI-based
combinations (n= 856, 32%, Table 1).
Chemotherapy-based
In the CR1 cohort, 213 patients (14%) received CC. These
regimens consisted of Busulfan/Cyclophosphamide (Bu/Cy,
n= 68), Bu/Cy/Etoposide (Bu/Cy/Eto, n= 66), Bu/Cytar-
abine (AraC)/+/−Melphalan (Mel, n= 23), Bu/Cy/Mel
(n= 20), Bu/Fludarabine (Flu, n= 20), Bu/Cy/Thiotepa
(Thio, n= 14), and Bu/Flu/Thio (n= 2).
In the CR2 cohort, 211 patients (14%) received CC.
These regimens consisted of Bu/Cy (n= 68), Bu/Cy/Eto
(n= 52), Bu/AraC/+/−Mel (n= 35), Bu/Cy/Thio (n= 18),
Bu/Cy/Mel (n= 17), Bu/Flu (n= 13), and Bu/Flu/Thio
(n= 8, Table 1).
Outcomes
Patients transplanted in CR1
Five years OS was 68.8% (95% CI 66.3–71.5) after FTBI
and 74.1% (95% CI 71.1–77.3) after CC (P= 0.25). Five
years LFS was 63.8% (95% CI 61.2–66.5) after FTBI and
61.4% (95% CI 58.0–64.9) after CC (P= 0.83). Five years
RI was 22.4% (95% CI 20.1–25.0) after FTBI and 26.9%
(95% CI 19.7–36.9) after CC (P= 0.33). Five years NRM
was 13.8% (95% CI 11.9–15.9) after FTBI and 11.7% (95%
CI 6.9–19.8) after CC (P= 0.47). Incidence of aGvHD
grade III–IV at day 100 was 11.8% (95% CI 10.1–13.7)
after FTBI and 16.9% (95% CI 10.7–26.7) after CC (P=
0.16). Five years incidence of cGvHD was 24.3% (95% CI
21.8–27.1) after FTBI and 20.8% (95% CI 13.7–31.4) after
CC (P= 0.60). Five years incidence of extensive cGvHD
was 11.3% (95% CI 9.5–13.4) after FTBI and 8.2% (95%
CI 4.3–15.9) after CC (P= 0.54, Table 2, Fig. 1a).
Patients transplanted in CR2
FTBI was superior compared with CC in terms of OS, LFS,
RI, and NRM. In detail, five years OS was 58.5% (95% CI
56.2–61.6) after FTBI and 35.9% (95% CI 33.0–39.1) after
CC (P < 0.0001). Five years LFS was 53.7% (95% CI
51.1–56.5) after FTBI and 29.4% (95% CI 26.6–32.5) after
CC (P < 0.0001). Five years RI was 30.6% (95% CI
28.1–33.3) after FTBI and 49.3% (95% CI 40.3–60.2) after
CC (P < 0.0001). Five years NRM was 15.7% (95% CI
13.8–17.9) after FTBI and 21.3% (95% CI 15.1–30.2) after
CC (P= 0.044).
Significant differences in the incidence of aGvHD grade
III–IV at day 100, cGvHD and extensive cGvHD were not
detected (Table 2, Fig. 1b).
Discussion
Most pediatric patients with ALL aged above 2 years who
undergo allo-HSCT receive FTBI as part of the preparative
regimen [1–5, 8–10, 12, 13, 15–17]. Adverse late effects
such as endocrine disorders, infertility, cognitive impair-
ment, cataracts, and increased risk for secondary malig-
nancies, are a major burden of this treatment modality but
can at least to a certain extent also occur after CC (e.g., Bu/
Cy/Eto) [18–22]. However, to date, it has not been proven
whether FTBI could be advantageously omitted from the
preparation for allo-HSCT and replaced by CC without
jeopardizing LFS [3, 5, 24, 25, 34]. Nevertheless, myeloa-
blative CC remains widely applied in Europe and else-
where. To compare outcomes of FTBI with CC in pediatric
ALL, we performed this multinational retrospective study.
Our study cohort has been intentionally restricted to patients
having received first allo-HSCT in CR1 or CR2 after MAC,
BM or PBSC as stem cell source from MRD or UD as donors
in order to receive a more uniform cohort. In this study, all CC
regimens were Bu-based. Bu/Cy, a well-established pre-
parative regimen for pediatric [35–37] and adult patients
[38, 39], was most frequently applied. Bu/Cy/Eto was the
second most frequently used MAC. This combination was
applied in the international Berlin–Frankfurt–Münster (iBFM/
BFM) clinical trials [1, 40, 41], particularly in infants (Inter-
fant-99) [42, 43], and elsewhere [2, 44–47]. Within the
observation period of this study, the alternative alkylator,
treosulfan, was increasingly used for children with malig-
nancies; but no treosulfan-containing regimen reached a sig-
nificant number of cases [48].
The FTBI and the CC group differed with regard to
number of cases, as well as some clinical features, as
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mentioned above (see Statistical analysis). These potential
confounders have been adjusted by the inverse IPW method
(propensity score) in order to allow the comparison of the
outcomes of the two conditioning groups.
In the CR1 cohort the outcome after FTBI was not sig-
nificantly different compared with CC. This is a new, inter-
esting finding; although we do not know the reasons for
omission of FTBI, which could be manifold: (1) young age,
(2) negativity of minimal residual disease before allo-HSCT,
(3) high risk for toxicity and infection after having experienced
complications during front line therapy, (4) logistical reasons
as no access to timely FTBI, and (5) decision of patients/
parents. However, due to the large number of participating
centers from various countries, there might be some equipoise.
Not surprisingly, overall outcomes of the CR2 cohort
were inferior compared with CR1 patients. This was
predominantly attributed to a significantly higher RI in
the CC group of the CR2 cohort. It was impossible to
evaluate risk factors for this difference. One could spec-
ulate, that patients with increased risk for toxicity due to
pretransplant complications and/or a history of cranial/
spinal irradiation were stratified to an irradiation-free
conditioning.
Interestingly, outcomes after FTBI were superior as
compared with CC with regard to OS, LFS, RI, and NRM in
our CR2 cohort. More importantly, superior OS, LFS, and
RI of the FTBI cohort did not result in a higher but even a
lower NRM compared with the CC cohort.
Table 2 Weighted analysis of survival by conditioning regimen of patients in CR1 and CR2.
Outcome Strata n Day 100 (95% CI) 1 year (95% CI) 3 years (95% CI) 5 years (95% CI) HR 95% CI P value*
CR1 (n= 1483)
OS FTBI 1271 – 81.8 (79.7–83.8) 72.5 (70.1–75.0) 68.8 (66.3–71.5) 1.00 – 0.25
CC 212 – 83.2 (80.7–85.8) 77.1 (74.2–80.0) 74.1 (71.1–77.3) 0.79 0.53–1.17
LFS FTBI 1271 – 74.7 (72.4–77.0) 65.8 (63.3–68.5) 63.8 (61.2–66.5) 1.00 – 0.83
CC 212 – 75.4 (72.5–78.4) 65.5 (62.3–68.9) 61.4 (58.0–64.9) 1.03 0.76–1.41
RI FTBI 1271 – 13.9 (12.1–16.1) 20.9 (18.7–23.4) 22.4 (20.1–25.0) 1.00 – 0.33
CC 212 – 16.9 (11.3–25.3) 24.9 (17.9–34.5) 26.9 (19.7–36.9) 1.20 0.83–1.71
NRM FTBI 1271 – 11.4 (9.7–13.3) 13.3 (11.5–15.4) 13.8 (11.9–15.9) 1.00 – 0.47
CC 212 – 7.7 (4.1–14.7) 9.6 (5.5–17.0) 11.7 (6.9–19.8) 0.79 0.41–1.50
aGvHD III–IV FTBI 1225 11.8 (10.1–13.7) – – – 1.00 – 0.16
CC 207 16.9 (10.7–26.7) – – – 1.46 0.86–2.50
cGvHD FTBI 1123 – 20.0 (17.6–22.6) 23.3 (20.9–26.1) 24.3 (21.8–27.1) 1.00 – 0.60
CC 189 – 18.5 (11.8–29.1) 20.8 (13.7–31.4) 20.8 (13.7–31.4) 0.86 0.50–1.48
cGvHD ext. FTBI 1107 – 8.2 (6.7–10.0) 10.4 (8.7–12.4) 11.3 (9.5–13.4) 1.00 – 0.54
CC 189 – 6.5 (3.1–13.8) 8.2 (4.3–15.9) 8.2 (4.3–15.9) 0.82 0.42–1.58
CR2 (n= 1549)
OS FTBI 1339 – 73.1 (70.8–75.4) 61.9 (59.4–64.5) 58.8 (56.2–61.6) 1.00 – <0.0001
CC 210 – 61.0 (58.1–64.1) 44.1 (41.1–47.4) 35.9 (33.0–39.1) 1.75 1.36–2.27
LFS FTBI 1339 – 65.1 (62.6–67.6) 55.5 (52.9–58.2) 53.7 (51.1–56.5) 1.00 – <0.0001
CC 210 – 45.9 (43.0–49.1) 34.2 (31.3–37.3) 29.4 (26.6–32.5) 1.80 1.43–2.25
RI FTBI 1339 – 21.9 (19.7–24.3) 29.5 (27.0–32.2) 30.6 (28.1–33.3) 1.00 – <0.0001
CC 210 – 35.4 (27.3–45.9) 45.6 (36.8–56.5) 49.3 (40.3–60.2) 1.96 1.44–2.67
NRM FTBI 1339 – 13.0 (11.3–15.0) 15.0 (13.2–17.2) 15.7 (13.8–17.9) 1.00 – 0.044
CC 210 – 18.7 (12.7–27.4) 20.2 (14.1–29.0) 21.3 (15.1–30.2) 1.51 1.01–2.25
aGvHD III–IV FTBI 1274 13.1 (11.4–15.1) – – – 1.00 – 0.36
CC 204 10.6 (6.5–17.2) – – – 0.80 0.51–1.28
cGvHD FTBI 1192 – 17.9 (15.7–20.4) 20.5 (18.1–23.1) 21.2 (18.8–23.9) 1.00 – 0.064
CC 184 – 25.3 (17.7–36.2) 25.8 (18.1–36.7) 26.0 (18.3–36.9) 1.52 0.98–2.37
cGvHD ext. FTBI 1178 – 7.5 (6.1–9.3) 9.6 (8.0–11.5) 9.9 (8.3–11.9) 1.00 – 0.075
CC 184 – 9.5 (5.7–16.1) 10.0 (6.0–16.5) 10.1 (6.2–16.7) 1.64 0.95–2.84
a/cGvD acute/chronic graft versus host disease, CC chemotherapy-based conditioning, CI confidence interval, CR1 first complete remission, CR2
second complete remission, ext. extensive, FTBI fractionated total body irradiation, HR Hazard ratio, LFS leukemia-free survival, NRM nonrelapse
mortality, OS overall survival, RI relapse incidence.
*Wald test in a weighted Cox model taking into account the center effect (cause specific for RI, NRM, and GvHD outcomes).
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Various hypotheses concerning the different impact of
FTBI on conditioning of ALL patients in CR1 versus CR2
can be made. One could speculate that:
(1) In a retrospective study there is no possibility to
identify the background of the decision for the given
conditioning. Patients in CR1 with unfavorable
prognostic factors might have been conditioned with
FTBI and those children with a more favorable risk
profile might have been treated with CC. This
hypothesis might similarly fit to patients in CR2.
(2) Patients in CR2 had more often extra medullary
leukemia and would benefit from FTBI.
(3) Relapsed ALL was more resistant to chemotherapeu-
tic agents and benefited from FTBI as a new treatment
element.
The potential superiority of FTBI-based conditioning in
pediatric ALL was also demonstrated in literature. In 2000,
Davies et al. reported a 3-year LFS of 50% after FTBI
versus 35% after Bu-based conditioning (P= 0.005) in a
cohort of 627 pediatric patients mainly transplanted in CR1
and CR2 [26]. Three years later, Bunin et al. found a 3-year
EFS of 58% after FTBI versus 29% after Bu-based con-
ditioning (P= 0.03) in a randomized cohort of 43 children,
transplanted in CR1-3 [2].
The main merit of our study is that it includes a large
cohort of pediatric ALL patients who, while in remission,
received FTBI as well as myeloablative CC for first allo-
HSCT using BM and PBSC from MRD and UD following
to several European protocols [39, 40]. Consequently, this
retrospective study represents “real-world practice.” On the
other hand, this registry-based study has some limitations
resulting in the fact that our results must be considered as
preliminary. In fact, no data were available on: (1) The
administration mode of Bu (intravenous or oral) or use of
therapeutic drug monitoring and dose adjustment. (2)
Cytogenetics or molecular genetics of ALL. (3) Toxicity or
reasons for NRM. (4) Secondary malignancies. (5) Minimal
residual disease levels at time of allo-HSCT. (6) Site of
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Fig. 1 Survival by conditioning regimen. a Outcomes of patients in
CR1. b Outcomes of patients in CR2. CC chemotherapy-based con-
ditioning, CR1 first complete remission, CR2 second complete
remission, FTBI fractionated total body irradiation, LFS leukemia-free
survival, NRM nonrelapse mortality, OS overall survival, RI relapse
incidence.
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relapse after front line ALL therapy or after allo-HSCT. (7)
CNS involvement. (8) Date of relapse for patients in CR2.
The latter information is necessary for classifying a relapse
event as very early, early or late for further patient stratifi-
cation in classes of risk [49], and for a more detailed ana-
lysis of the survival of patients transplanted in CR2.
Furthermore, since our retrospective study cohort included
B- as well as T-ALL phenotypes, BM and PBSC as stem
cell sources, MRD and UD, only children above 2 years of
age and spanned an observation time of 13 years, our study
population still has a heterogeneous character. Moreover,
our non-FTBI-receiving CC cohort is relatively small
compared with the FTBI group.
We conclude that FTBI-based conditioning was superior
to CC in terms of OS, LFS, RI, and NRM for children
undergoing allo-HSCT in CR2, according to the largest
study comparing outcomes of FTBI versus CC for first allo-
HSCT in pediatric ALL. However, we must stress the
preliminary character of the results of this retrospective
“real-world-practice” study.
Prospective data comparing FTBI and CC for allo-HSCT
in children and adolescents with ALL are urgently needed.
Due to the limitations of retrospective studies, it seemed
justified to ask whether CC is at least as effective as a FTBI-
based conditioning in terms of outcome, toxicity, and late
effects in a prospective, preferably randomized clinical trial.
The answer to this relevant question will be hopefully
obtained by the prospective international, multicenter ALL
SCTped 2012 FORUM (“For Omitting Radiation Under
Majority Age”) randomized trial, which was initiated in
2012 (EudraCT number: 2012-003032-22).
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